Elelyso® (taliglucerase alfa)

Elelyso (taliglucerase alfa) is covered only for the FDA‑approved indication of Type 1 Gaucher disease in patients aged ≥4 years with diagnosis confirmed by deficient β‑glucocerebrosidase activity (leukocytes or fibroblasts) or by molecular genetic testing; use in patients <4 years or for non‑FDA indications is excluded. Approval requires prescribing by or consultation with a geneticist, endocrinologist, metabolic disorder/lysosomal storage disorder specialist, documentation of age and diagnostic testing, dosing of 60 U/kg IV every other week, and is authorized for up to one year.

"Elelyso is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.